Hospital.Help

Amsterdam – The European Medicines Agency (EMA) has revised its negative vote on the Alzheimer’s drug Lecanemab and is now recommending its approval to the European Commission (EU Commission). The assessment refers to the “treatment of mild cognitive impairment (memory and thinking disorders) or mild dementia as a result of Alzheimer’s disease in patients who have only one or no copy of ApoE4, a…